EGFR and non-small cell lung carcinoma: The NEOADAURA study is a randomized phase III study designed to determine the major pathologic response rate in patients with clinical stage II–III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation after neoadjuvant (1) chemotherapy, (2) osimertinib alone, or (3) osimertinib plus chemotherapy.